LU-ATMP: Lund University Advanced Therapy Medicinal Products
1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Bi-allelic NRXN1α deletion in microglia derived from iPSC of an autistic patient increases interleukin-6 production and impairs supporting function on neuronal networking
(
- Contribution to journal › Article
-
Mark
Autologous cells, no longer lost in translation
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Defined culture conditions robustly maintain human stem cell pluripotency, highlighting a role for Ca2+ signaling
(
- Contribution to journal › Article
-
Mark
Editorial : Allergen-specific antibodies: from basic science to clinical application
(
- Contribution to journal › Debate/Note/Editorial
- 2024
-
Mark
Mammalian cell display with automated oligo design and library assembly allows for rapid residue level conformational epitope mapping
(
- Contribution to journal › Article
-
Mark
Pre-clinical evaluation of clinically relevant iPS cell derived neuroepithelial stem cells as an off-the-shelf cell therapy for spinal cord injury
(
- Contribution to journal › Article
-
Mark
Protective Non-neutralizing anti-N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence
(
- Contribution to journal › Article
-
Mark
High-throughput neural stem cell-based drug screening identifies S6K1 inhibition as a selective vulnerability in sonic hedgehog-medulloblastoma
(
- Contribution to journal › Article
-
Mark
The hinge-engineered IgG1-IgG3 hybrid subclass IgGh47 potently enhances Fc-mediated function of anti-streptococcal and SARS-CoV-2 antibodies
(
- Contribution to journal › Article